Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ammonia** is an inorganic small molecule, chemically designated NH3, used in ammonia inhalant products as a rapidly acting respiratory stimulant for prevention or treatment of fainting. Inhaled ammonia vapor produces intense local irritation of nasal and upper-airway sensory mucosa, triggering an inhalation and sympathetic arousal reflex rather than acting through a defined molecular drug target. In a completed randomized crossover study in military cadets undergoing approximately 36 hours of total sleep deprivation, ammonia inhalation modestly improved simple reaction time and jump height but did not mitigate the overall performance effects of sleep deprivation. ([journals.plos.org](https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0293804))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ammonia.